Leap Therapeutics stock hits 52-week low at $0.39

Leap Therapeutics Inc . (NASDAQ:LPTX) shares have tumbled to a 52-week low, touching down at $0.39, with the micro-cap biotech now valued at just $14.94 million. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value. This latest price level reflects a stark downturn for the biotech firm, which has seen its stock value erode by -83.41% over the past year. Investors have been grappling with a challenging period for the company, marked by rapid cash burn and weak financial health scores. Despite maintaining a healthy current ratio of 3.97, internal factors and market dynamics have contributed to the significant decline in share price. The 52-week low serves as a critical indicator of the current bearish sentiment surrounding the stock, and market watchers are closely monitoring Leap Therapeutics’ strategies for recovery and growth in the coming quarters. With analysts maintaining a $3 price target, investors seeking deeper insights into LPTX’s financial health and growth prospects can access additional analysis through InvestingPro, which offers 13 more exclusive tips about the company.

In other recent news, Leap Therapeutics has reported positive initial data from its DeFianCe study for advanced colorectal cancer (CRC). The Phase 2 trial showed a higher objective response rate (ORR) with the drug sirexatamab in combination with bevacizumab and chemotherapy, achieving a 35% ORR compared to 23% in the control arm. Despite this progress in CRC, the company faced setbacks in its DisTinGuish study for advanced gastric cancer, as the trial did not meet the primary progression-free survival endpoints, leading Leap Therapeutics to discontinue plans for Phase 3 studies in this indication. Consequently, the company is redirecting resources towards CRC and seeking strategic partnerships for further development in gastric cancer and other indications with high DKK1 expression.

Analysts have responded to these developments by adjusting their ratings. H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral, citing concerns over the future progress of sirexatamab, particularly in gastric cancer. Similarly, Baird analyst Joel Beatty revised the stock rating to Neutral from Outperform and significantly reduced the price target to $1.25 from $9.00, reflecting the ambiguous survival data and the company’s financial outlook. These analyst downgrades highlight the cautious stance taken due to the mixed clinical trial outcomes and uncertain strategic direction. Leap Therapeutics remains optimistic about the CRC data and is preparing for a registrational Phase 3 study, focusing on patients with high unmet needs and specific biomarker profiles.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.